 Connection
Christina Chambers to Abnormalities, Drug-Induced
This is a "connection" page, showing publications Christina Chambers has written about Abnormalities, Drug-Induced.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.871 |
|
|
|
-
Chambers CD, Johnson DL, Luo Y, Xu R, Adam MP, Braddock SR, Jones KL. Birth Outcomes in Women Who Have Taken Vedolizumab in Pregnancy: Results From the Vedolizumab Pregnancy Exposure Registry. Am J Gastroenterol. 2026 Mar 01; 121(3):720-732.
Score: 0.896
-
Vukusic S, Coyle PK, Jurgensen S, Truffinet P, Benamor M, Afsar S, Purvis A, Poole EM, Chambers C. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Mult Scler. 2020 06; 26(7):829-836.
Score: 0.584
-
Bérard A, Wisner KL, Hultzsch S, Chambers C. Field studies versus database studies on the risks and benefits of medication use during pregnancy: Distinct pieces of the same puzzle. Reprod Toxicol. 2016 04; 60:123-8.
Score: 0.469
-
Feldman HS, Jones KL, Lindsay S, Slymen D, Klonoff-Cohen H, Kao K, Rao S, Chambers C. Patterns of prenatal alcohol exposure and associated non-characteristic minor structural malformations: a prospective study. Am J Med Genet A. 2011 Dec; 155A(12):2949-55.
Score: 0.348
-
Sillis L, Heinonen EW, Ceulemans M, Foulon V, Luo Y, Johnson D, Chambers CD. Medications for Nausea and Vomiting of Pregnancy and the Risks for Adverse Birth Outcomes. Pharmacoepidemiol Drug Saf. 2026 Apr; 35(4):e70367.
Score: 0.237
-
Ewig CLY, Wang Y, Smolinski NE, Toyserkani GA, LaCivita C, Lackey L, Eggers S, Sahin L, Abu-Rustum RS, Bateman BT, Berard A, Chambers CD, Choby B, Conover EA, Greene MF, Hernández-Díaz S, Jamieson DJ, Obican SG, Polifka JE, Roussos-Ross K, Sheffield JS, Lavigne SV, Zimmermann EM, Laffan SB, DeLise AM, Gilsenan AW, Hammad TA, Hampp C, Hardy JR, Knox CA, Shields K, Smith MY, Sobel RE, Tassinari MS, Maro JC, Rasmussen SA, Winterstein AG. Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation Strategies. Drug Saf. 2025 Dec; 48(12):1387-1397.
Score: 0.226
-
Lyons Jones K, Johnson DL, Chambers CD. Monitoring leflunomide (Arava) as a new potential teratogen. Teratology. 2002 May; 65(5):200-2.
Score: 0.181
-
Jones KL, Johnson KA, Dick LM, Felix RJ, Kao KK, Chambers CD. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. Teratology. 2002 Mar; 65(3):125-30.
Score: 0.178
-
Meserve J, Luo J, Zhu W, Veeravalli N, Bandoli G, Chambers CD, Singh AG, Boland BS, Sandborn WJ, Mahadevan U, Singh S. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology. 2021 07; 161(1):107-115.e3.
Score: 0.167
-
Xu R, Hou J, Chambers CD. The impact of confounder selection in propensity scores when applied to prospective cohort studies in pregnancy. Reprod Toxicol. 2018 06; 78:75-80.
Score: 0.136
-
Bandoli G, Palmsten K, Flores KF, Chambers CD. Constructing Causal Diagrams for Common Perinatal Outcomes: Benefits, Limitations and Motivating Examples with Maternal Antidepressant Use in Pregnancy. Paediatr Perinat Epidemiol. 2016 09; 30(5):521-8.
Score: 0.119
-
Broussard CS, Frey MT, Hernandez-Diaz S, Greene MF, Chambers CD, Sahin L, Collins Sharp BA, Honein MA. Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention--convened meeting. Am J Obstet Gynecol. 2014 Sep; 211(3):208-214.e1.
Score: 0.104
-
Felix RJ, Jones KL, Johnson KA, McCloskey CA, Chambers CD. Postmarketing surveillance for drug safety in pregnancy: the Organization of Teratology Information Services project. Birth Defects Res A Clin Mol Teratol. 2004 Dec; 70(12):944-7.
Score: 0.054
-
Mahadevan U, Levy G, Gensler L, Ali M, Lacerda AP, Wegrzyn L, Palac H, Bhutani-Jacques T, Long M, Clowse MEB, Kimball AB, Chambers C, Scialli AR. Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports. Drug Saf. 2024 Oct; 47(10):1039-1049.
Score: 0.053
-
Bandoli G, Jones K, Wertelecki W, Yevtushok L, Zymak-Zakutnya N, Granovska I, Plotka L, Chambers C. Patterns of Prenatal Alcohol Exposure and Alcohol-Related Dysmorphic Features. Alcohol Clin Exp Res. 2020 10; 44(10):2045-2052.
Score: 0.040
-
Clowse MEB, Scheuerle AE, Chambers C, Afzali A, Kimball AB, Cush JJ, Cooney M, Shaughnessy L, Vanderkelen M, Förger F. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol. 2018 09; 70(9):1399-1407.
Score: 0.035
-
Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016 May; 75(5):795-810.
Score: 0.029
-
Robertson J, Polifka JE, Avner M, Chambers C, Delevan G, Koren G, Lavigne SV, Martinez LP, Miller RK, Carey JC. A survey of pregnant women using isotretinoin. Birth Defects Res A Clin Mol Teratol. 2005 Nov; 73(11):881-7.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|